Warning (2) : Undefined array key "profile" [in /var/www/vhosts/marketcap.tools/httpdocs/src/Controller/HomesController.php, line 242]
Warning (2) : Trying to access array offset on value of type null [in /var/www/vhosts/marketcap.tools/httpdocs/src/Controller/HomesController.php, line 242]
Warning (2) : Undefined array key "profile" [in /var/www/vhosts/marketcap.tools/httpdocs/src/Controller/HomesController.php, line 243]
Warning (2) : Trying to access array offset on value of type null [in /var/www/vhosts/marketcap.tools/httpdocs/src/Controller/HomesController.php, line 243]
Warning (512) : Unable to emit headers. Headers sent in file=/var/www/vhosts/marketcap.tools/httpdocs/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php line=36 [in /var/www/vhosts/marketcap.tools/httpdocs/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 71]
Warning (2) : Cannot modify header information - headers already sent by (output started at /var/www/vhosts/marketcap.tools/httpdocs/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php:36) [in /var/www/vhosts/marketcap.tools/httpdocs/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 164]
Warning (2) : Cannot modify header information - headers already sent by (output started at /var/www/vhosts/marketcap.tools/httpdocs/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php:36) [in /var/www/vhosts/marketcap.tools/httpdocs/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 197]
Warning (2) : Cannot modify header information - headers already sent by (output started at /var/www/vhosts/marketcap.tools/httpdocs/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php:36) [in /var/www/vhosts/marketcap.tools/httpdocs/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 236]
Sera Prognostics, Inc. - Market capitalization
Sera Prognostics, Inc.
SERA

$202.73 M
Marketcap
$6.18
Share price
Country
N/A
Change (1 day)
N/A
Year High
N/A
Year Low

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

marketcap